One of the most practical questions clinics ask about compounded semaglutide is: how long does it last after reconstitution? The answer is not a single number — it depends on the formulation, the diluent used, the storage conditions, and the compounding pharmacy's specific stability data.

This post gives you a clear framework for understanding post-reconstitution shelf life for compounded semaglutide, what factors affect it, and how to manage it in your clinic.

Compounded semaglutide is available in two primary forms, and the shelf life question is different for each:

Lyophilized (freeze-dried) semaglutide: Comes as a dry powder in a sealed vial. Has a longer pre-reconstitution shelf life. Once reconstituted with a diluent, the clock starts on the post-reconstitution BUD.

Liquid (aqueous solution) semaglutide: Comes as a ready-to-use solution. No reconstitution required. The BUD applies from the time of compounding.

For lyophilized preparations, there are effectively two BUDs to track: the pre-reconstitution BUD (printed on the original label) and the post-reconstitution BUD (which begins when you add the diluent).

Under USP <797> (2023 revision), the post-reconstitution BUD for a sterile preparation depends on:

Category 1 vs. Category 2: As discussed in earlier posts, Category 1 preparations have shorter default BUDs (12 hours at room temperature, 24 hours refrigerated). Category 2 preparations can have longer BUDs if the pharmacy has conducted appropriate sterility testing and stability studies.

Preservative status: Preparations reconstituted with bacteriostatic water for injection (BWFI, which contains 0.9% benzyl alcohol) have longer post-reconstitution BUDs than preparations reconstituted with sterile water for injection (SWFI, which contains no preservative). The preservative inhibits microbial growth, extending the safe use period.

Stability data: A pharmacy that has conducted extended stability testing on its reconstituted semaglutide preparation can assign a longer BUD than the USP defaults, provided the data supports it.

Based on USP <797> guidelines and common pharmacy practices, typical post-reconstitution BUDs for compounded semaglutide are:

Reconstituted with BWFI, refrigerated, Category 2:

• Typically 14–28 days, depending on the pharmacy's stability data
• Some pharmacies with robust stability programs may assign up to 45 days

Reconstituted with SWFI, refrigerated:

• Typically 24 hours (unpreserved preparations should be used promptly)
• Not practical for multi-dose use

Reconstituted with BWFI, room temperature:

• Not recommended for extended storage — refrigerate after reconstitution

These are general ranges. Your specific pharmacy partner's assigned BUD may differ based on their formulation and stability data. Always follow the pharmacy's specific instructions.

This surprises many clinics. A lyophilized vial might have a pre-reconstitution BUD of 60 or 90 days, but once reconstituted, the BUD drops to 14–28 days. Why?

The answer is chemistry. In the dry lyophilized state, the semaglutide molecule is protected from the degradation reactions that require water — hydrolysis, oxidation, and aggregation. Once you add water (the diluent), those reactions can proceed. The post-reconstitution BUD reflects how long the preparation remains within acceptable quality limits in the aqueous state.

This is why it is critical to:

1. Only reconstitute what you need for the near term
2. Label the reconstituted vial with the reconstitution date and post-reconstitution BUD
3. Never use a reconstituted preparation past its post-reconstitution BUD

Managing post-reconstitution BUDs in a busy clinic requires a systematic approach:

Reconstitute in batches that match your patient volume. If you have 10 patients receiving semaglutide injections over the next two weeks, reconstitute enough for those 10 patients — not a month's supply.

Label every reconstituted vial immediately. The label should include the reconstitution date, time, post-reconstitution BUD, and the initials of the person who performed the reconstitution.

Use a first-in, first-out (FIFO) system. Use reconstituted vials in the order they were prepared, so older preparations are used before newer ones.

Track BUDs in your inventory system. Whether you use a paper log or electronic system, track the post-reconstitution BUD for every vial in your inventory. Flag vials that are approaching their BUD so they can be used or discarded in time.

Discard expired preparations. A preparation past its post-reconstitution BUD must be discarded, regardless of appearance. Do not administer preparations past their BUD.

When sourcing lyophilized compounded semaglutide, ask your pharmacy partner:

1. What is the post-reconstitution BUD for your preparation?
2. What diluent do you recommend, and what volume?
3. Is the post-reconstitution BUD based on USP defaults or extended stability testing?
4. Do you have stability data for the reconstituted preparation?
5. What are the storage conditions after reconstitution?

A pharmacy that cannot answer these questions clearly may not have a rigorous stability program. That is a risk for your clinic.

Even within the post-reconstitution BUD, discard a preparation if you observe:

• Cloudiness or turbidity (should be clear)
• Visible particles (should be particle-free)
• Unusual color (should be colorless to slightly yellow)
• Persistent foam that does not dissipate
• Evidence of temperature excursion (left out of refrigerator for extended period)
• Damaged or compromised vial or stopper

When in doubt, discard and reconstitute a new vial. Patient safety is the priority.

1. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. 2023 Revision.
2. Manning MC, et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544–575.
3. Wang W. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics. 2000;203(1-2):1–60.
4. Allen LV Jr. Stability and Beyond-Use Dating of Compounded Preparations. International Journal of Pharmaceutical Compounding. 2019;23(4):272–278.
5. Institute for Safe Medication Practices. ISMP Guidelines for Safe Preparation of Compounded Sterile Preparations. ISMP, 2016.

MedClinic Partners connects licensed clinics with vetted 503B supply partners for compounded GLP-1 access. Questions about semaglutide supply or BUD compliance? Use the Get Connected form to reach our team.